My key takeouts from attending the AGM:
JP's description of NNZ-2591 as a 'platform drug'
The phase 1 trials taking place for several undisclosed orphan conditions
JP's comment from the previous day of the Reata t/o and the price generated of 7.3b
JP looking like he's in the final few kms of a marathon
My conclusion (which mirrors a couple of our esteemed posters of 2-3 weeks ago):
Successful Angelman trial results + 3-4 phase 1 results in new conditions and gene mutations = takeover
Ann: AGM Chair Address & CEO Presentation, page-28
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |